---

title: "Recommended long COVID outcome measures and their implications for clinical trial design, with a focus on post-exertional malaise"
tags:
- ➕ 2025-12-25
- ⏳ Trial
created: '2025-12-19'
published: '2025-12-19'

---


<details>
<summary>Soares et al. (2025)</summary>

- **Authors:** Letícia Soares, Hannah Davis, Ezra Spier, Tiffany Walker, Todd Davenport, David Putrino, Michael Peluso, Julia Moore Vogel.
- **Institutes:** Patient-Led Research Collaborative; Icahn School of Medicine at Mount Sinai; University of the Pacific; Emory University School of Medicine; University of California, San Francisco; Scripps Research Translational Institute.
- **Publisher:** EBioMedicine
- **Link:** [DOI](https://doi.org/10.1016/j.ebiom.2025.106083)

</details>


## Summary

This study provides a vital roadmap for improving the quality of clinical research for both Long COVID and ME/CFS. By emphasizing the need for objective and patient-relevant metrics, especially regarding post-exertional malaise, it aims to shift the scientific field away from flawed "one-size-fits-all" studies toward more precise and safe research. For patients, this means that future clinical trials are more likely to correctly identify treatments that work while avoiding protocols that could lead to post-exertional crashes.

## What was researched?

This paper establishes a framework for selecting and implementing "outcome measures"—the specific tools and scales used to determine if a treatment is working—in Long COVID clinical trials. The researchers focused specifically on how to accurately capture post-exertional malaise (PEM), the worsening of symptoms after even minor exertion, which is often missed in standard medical studies.

## Why was it researched?

The research was prompted by the high failure rate and poor design of existing Long COVID clinical trials, which often rely on generic tools that fail to account for the core features of the illness. Without standardized, validated ways to measure symptoms like PEM and cognitive dysfunction, effective treatments cannot be properly identified, and some trial protocols may even risk harming patients by ignoring the danger of exertional triggers.

## How was it researched?

This was a comprehensive "Personal View" and expert review that synthesized current clinical challenges with patient-led research data. The authors—a team of clinicians, physical therapists, and patient-researchers—analyzed existing trial methodologies and developed five overarching recommendations for future research. They also curated a list of existing and candidate outcome measures specifically suited for tracking the fluctuating nature of Long COVID and ME/CFS symptoms over time.

## What has been found?

The authors identified five critical requirements for successful trials: thorough baseline characterization of patients, the collection of long-term longitudinal data, the use of placebo arms to account for the natural "waxing and waning" of the disease, the mandatory inclusion of PEM measurements, and the balancing of trial groups by disease severity and phenotype. They found that unless trials specifically measure PEM, they risk producing "false positives" or failing to detect real improvements in quality of life.

## Discussion

The authors discuss the limitations of current research, noting that many studies are too short or use overly broad definitions of "fatigue" that do not distinguish between tiredness and the systemic crash of PEM. They emphasize that the biological causes of Long COVID are likely diverse, meaning that trials must be designed to look at specific subgroups of patients rather than treating all participants as a single, uniform group.

## Conclusion & Future Work

The paper concludes that the development and validation of specific outcome measures must happen alongside the testing of new drugs to avoid wasting time and resources. Future work must focus on securing dedicated funding to validate these endpoints in large, diverse patient populations to ensure that clinical trials can accurately identify effective therapies.
